Abstract Library

#2812 SILVELUL Project: Development of an New Potential Predictive Immunohistochemical Score (SPI) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus

Introduction: Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET (Viúdez et al. Oncotarget 2016).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Viudez A

Authors: Viudez A, Crespo G, Gómez-Dorronsoro M, Benavent M, Hernando J,

Keywords: biomarker, PHLDA3, MGMT, IHC, NDRG1, CAPTEM, everolimus,

#996 Good Clinical Response to a Somatostatin Analog in a Patient with Metastatic Glucagonoma and Necrolytic Migratory Erythema: 5-Year Follow-Up

Introduction: Glucagonoma is a rare neuroendocrine tumor of the pancreas usually diagnosed in advanced stages or when necrolytic migratory erythema occurs.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Marín L

Authors: Marín L, Gómez D, Wandurraga E,

Keywords: glucagonoma, necrolytic migratory erithema, octreotide,

#980 ELECT: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel (LAN) Treatment for Carcinoid Syndrome (CS) in Patients (Pts) with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Introduction: Somatostatin analogs (SSAs) are the mainstay treatment

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Gomez-Panzani E, Vinik A, Wolin E, Audry H,

Keywords: symptom control,

#971 Well-differentiated Pancreatic Neuroendocrine Tumors: Prognostic Significance of Pathological Parameters

Introduction: Well-differentiated (WD) pancreatic neuroendocrine tumors (pNET) are uncommon neoplasms and one challenge lies in predicting tumor behavior and managing these patients.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Pérez-Casanova L, Serrano T, Navas C, Ruiz N, Gomez A,

Keywords: pancreas, well-differentiated G2,

#865 Diagnostic and Outcome Differences between Sporadic and Familial Cases of Pheochromocytoma and Paraganglioma: A Retrospective Cohort Study

Introduction: Hereditary Pheochromocytomas (PCC) and Paragangliomas (PGL) account for 30-35% of cases and have some clinically relevant peculiarities.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Ropero Luis G, Ruiz Gracia T, Gomez Hoyos E, Cuesta Hernandez M, Fernandez Capel F,

Keywords: pheochromocytoma, paraganglioma,